RxDoctor Payments Data

Holly Gay, APRN

Family · Panama City, FLNPI 1649941139

Payments from drug & device makers

$2,920in general payments, 2019–2025

Across 111 payments — averaging $26.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$756
  • Lilly USA, LLC$406
  • Idorsia Pharmaceuticals US Inc$131
  • Axsome Therapeutics, Inc.$126
  • Johnson & Johnson$82
  • plus $109 from 4 others

What the payments were for

  • Food & beverage$2,920100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,920 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$4,872
Medicare patients
42
Services billed
74

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$34,500
FarxigaDapagliflozin Propanediol15$19,876
JanuviaSitagliptin Phosphate11$10,237
Rosuvastatin Calcium97$2,984
Omeprazole64$1,206
Montelukast Sodium57$774
Amlodipine Besylate78$766
Atorvastatin Calcium55$746
Levothyroxine Sodium63$743
Losartan Potassium53$593
ProgesteroneProgesterone, Micronized15$578
Lisinopril85$558
Metformin Hcl57$497
Pravastatin Sodium20$484
Albuterol Sulfate HfaAlbuterol Sulfate11$477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,311$34,50024 claims
AstraZenecaFarxiga$756$19,87615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.

Other family in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →